-miRNA-4647 Axis in Colorectal Cancer: Prospects to Identifications of Risk Factors and Clinical Outcomes

Overview

Journal Oncol Lett

Specialty Oncology

Date 2023 Jan 23

PMID 36688110

Authors

Ladislav Sojka

Alena Opattova

Linda Bartu

Josef Horak

Vlasta Korenkova

Vendula Novosadova

Vera Krizkova

Jan Bruha

Vaclav Liska

Michaela Schneiderova

Ondrej Kubecek

Ludmila Vodickova

Marketa Urbanova

Jaromir Simsa

Pavel Vodicka

Veronika Vymetalkova

Affiliations

Soon will be listed here.

Abstract

MUC13, a transmembrane mucin glycoprotein, is overexpressed in colorectal cancer (CRC), however, its regulation and functions are not fully understood. It has been shown that MUC13 protects colonic epithelial cells from apoptosis. Therefore, studying MUC13 and MUC13-regulated pathways may reveal promising therapeutic approaches for CRC treatment. Growing evidence suggests that microRNAs (miRs) are involved in the development and progression of CRC. In the present study, the -miR-4647 axis was addressed in association with survival of patients. miR-4647 is predicted to bind to the gene and was analyzed by RT-qPCR in 187 tumors and their adjacent non-malignant mucosa of patients with CRC. The impact of previously mentioned genes on survival and migration abilities of cancer cells was validated Significantly upregulated (P=0.02) in was observed tumor tissues compared with non-malignant adjacent mucosa, while miR-4647 (P=0.05) showed an opposite trend. Higher expression levels of (log-rank P=0.05) were associated with worse patient's survival. The ectopic overexpression of studied miR resulted in decreased migratory abilities and worse survival of cells. Attenuated expression levels confirmed the suppression of colony forming of CRC cells. In summary, the present data suggested the essential role of MUC13-miR-4647 in patients' survival, and this axis may serve as a novel therapeutic target. It is anticipated MUC13 may hold significant potential in the screening, diagnosis and treatment of CRC.

Citing Articles

The Mucin Family of Proteins: Candidates as Potential Biomarkers for Colon Cancer.

Cox K, Liu S, Lwin T, Hoffman R, Batra S, Bouvet M Cancers (Basel). 2023; 15(5).

PMID: 36900282 PMC: 10000725. DOI: 10.3390/cancers15051491.

References

Zhu J, Xu Y, Liu S, Qiao L, Sun J, Zhao Q . MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy. Front Bioeng Biotechnol. 2020; 8:176. PMC: 7075808. DOI: 10.3389/fbioe.2020.00176. View

Jonckheere N, Skrypek N, Van Seuningen I . Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta. 2014; 1846(1):142-51. DOI: 10.1016/j.bbcan.2014.04.008. View

Sheng Y, Lourie R, Linden S, Jeffery P, Roche D, Tran T . The MUC13 cell-surface mucin protects against intestinal inflammation by inhibiting epithelial cell apoptosis. Gut. 2011; 60(12):1661-70. DOI: 10.1136/gut.2011.239194. View

Hao M, Wang K, Ding Y, Li H, Liu Y, Ding L . Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer. Eur J Med Res. 2022; 27(1):130. PMC: 9310475. DOI: 10.1186/s40001-022-00759-z. View

Lauriola M, Ugolini G, Rosati G, Zanotti S, Montroni I, Manaresi A . Identification by a Digital Gene Expression Displayer (DGED) and test by RT-PCR analysis of new mRNA candidate markers for colorectal cancer in peripheral blood. Int J Oncol. 2010; 37(2):519-25. DOI: 10.3892/ijo_00000701. View

Cervena K, Novosadova V, Pardini B, Naccarati A, Opattova A, Horak J . Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients. Front Oncol. 2021; 11:702258. PMC: 8444897. DOI: 10.3389/fonc.2021.702258. View

Brenner H, Kloor M, Pox C . Colorectal cancer. Lancet. 2013; 383(9927):1490-1502. DOI: 10.1016/S0140-6736(13)61649-9. View

Naccarati A, Pardini B, Hemminki K, Vodicka P . Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res. 2007; 635(2-3):118-145. DOI: 10.1016/j.mrrev.2007.02.001. View

Gupta B, Maher D, Ebeling M, Stephenson P, Puumala S, Koch M . Functions and regulation of MUC13 mucin in colon cancer cells. J Gastroenterol. 2013; 49(10):1378-91. PMC: 3979492. DOI: 10.1007/s00535-013-0885-z. View

10.

Wang X, Gao G, Chen Z, Chen Z, Han M, Xie X . Identification of the miRNA signature and key genes in colorectal cancer lymph node metastasis. Cancer Cell Int. 2021; 21(1):358. PMC: 8314594. DOI: 10.1186/s12935-021-02058-9. View

11.

Gupta B, Maher D, Ebeling M, Sundram V, Koch M, Lynch D . Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. J Histochem Cytochem. 2012; 60(11):822-31. PMC: 3524568. DOI: 10.1369/0022155412460678. View

12.

Liu C, Rennie W, Carmack C, Kanoria S, Cheng J, Lu J . Effects of genetic variations on microRNA: target interactions. Nucleic Acids Res. 2014; 42(15):9543-52. PMC: 4150780. DOI: 10.1093/nar/gku675. View

13.

Pidikova P, Herichova I . miRNA Clusters with Up-Regulated Expression in Colorectal Cancer. Cancers (Basel). 2021; 13(12). PMC: 8232258. DOI: 10.3390/cancers13122979. View

14.

Williams S, Wreschner D, Tran M, Eyre H, Sutherland G, McGuckin M . Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem. 2001; 276(21):18327-36. DOI: 10.1074/jbc.M008850200. View

15.

Kufe D . Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009; 9(12):874-85. PMC: 2951677. DOI: 10.1038/nrc2761. View

16.

Zhao Y, Zhang W, Huo M, Wang P, Liu X, Wang Y . XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer. Signal Transduct Target Ther. 2021; 6(1):357. PMC: 8526672. DOI: 10.1038/s41392-021-00761-7. View

17.

Witter K, Tonar Z, Matejka V, Martinca T, Jonak M, Rokosny S . Tissue reaction to three different types of tissue glues in an experimental aorta dissection model: a quantitative approach. Histochem Cell Biol. 2009; 133(2):241-59. DOI: 10.1007/s00418-009-0656-3. View

18.

Sheng Y, Triyana S, Wang R, Das I, Gerloff K, Florin T . MUC1 and MUC13 differentially regulate epithelial inflammation in response to inflammatory and infectious stimuli. Mucosal Immunol. 2012; 6(3):557-68. DOI: 10.1038/mi.2012.98. View

19.

Chauhan S, Ebeling M, Maher D, Koch M, Watanabe A, Aburatani H . MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther. 2011; 11(1):24-33. PMC: 4100478. DOI: 10.1158/1535-7163.MCT-11-0598. View

20.

Senapati S, Das S, Batra S . Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci. 2009; 35(4):236-45. PMC: 3030310. DOI: 10.1016/j.tibs.2009.10.003. View